Health Economics›Head and neck cancer›Recurrent or metastatic disease subsequent lines of therapy

Recurrent or metastatic disease subsequent lines of therapy

Head and neck cancer · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	8.4 mo	—	—	1
Afatinib monotherapy Variant #01	—	R 34 727	28d	2.8 mo	—	4	R 138 910 PFS proxy	2
Cetuximab monotherapy Variant #04	—	R 29 164	7d	—	6.9 mo	—	—	3
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	3.5 mo	3.1 mo	4	R 8 878 PFS proxy	2
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	5.1 mo	—	—	3
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	7.7 mo	—	—	1
Best supportive care Partial	—	—	—	—	5.2 mo	—	—	1
Methotrexate monotherapy Partial	—	—	—	2.2 mo	5.1 mo	—	—	7

8 of 8 regimens shown